Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later
Language English Country Great Britain, England Media print-electronic
Document type Clinical Trial, Journal Article, Observational Study, Research Support, Non-U.S. Gov't
PubMed
26362893
DOI
10.1177/1352458515601903
PII: 1352458515601903
Knihovny.cz E-resources
- Keywords
- MRI, Multiple sclerosis, blood–brain barrier, brain atrophy, clinically isolated syndrome, disability,
- MeSH
- Albumins cerebrospinal fluid MeSH
- Atrophy pathology MeSH
- Biomarkers MeSH
- Adult MeSH
- Blood-Brain Barrier * MeSH
- Humans MeSH
- Young Adult MeSH
- Brain diagnostic imaging pathology MeSH
- Follow-Up Studies MeSH
- Disease Progression * MeSH
- Multiple Sclerosis blood cerebrospinal fluid physiopathology MeSH
- Serum Albumin MeSH
- Severity of Illness Index * MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Albumins MeSH
- Biomarkers MeSH
- Serum Albumin MeSH
BACKGROUND: The utility of blood-brain barrier (BBB) biomarkers for clinical and magnetic resonance imaging progression in multiple sclerosis (MS) has not been extensively investigated. OBJECTIVES: To determine whether cerebrospinal fluid (CSF) measures of BBB at clinical onset predict radiological and clinical deterioration over 48 months. METHODS: This longitudinal study included 182 patients after first clinical event suggestive of MS treated with weekly intramuscular interferon beta-1a. CSF and serum samples were analyzed for leukocytes, total protein, albumin, immunoglobulins, and oligoclonal bands. Optimal thresholds for the albumin quotient (QAlb) were determined. Mixed-effect model analyses, adjusted for age, gender, and treatment escalation, were used to analyze relationship between CSF measures and disease activity outcomes over 48 months of follow-up. RESULTS: Increased QAlb at clinical onset was associated with enlargement of lateral ventricles (p = .001) and greater whole brain (p = .003), white matter (p < .001), corpus callosum (p < .001), and thalamus (p = .003) volume loss over 48 months. Higher QAlb was associated with higher Expanded Disability Status Scale score over 48 months (p = .002). CONCLUSIONS: Increased QAlb at clinical onset is associated with increased brain atrophy and greater disability in patients after first clinical event suggestive of MS.
Department of Neurology State University of New York Buffalo NY USA
Department of Neurology University Hospital Ostrava Czech Republic
References provided by Crossref.org
Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients
